Verapamyl in the treatment of paroxysmal supraventricular tachycardia

DENNIS M. KRIKLER
M.D., F.R.C.P., F.A.C.C.

Cardiovascular Division, Royal Postgraduate Medical School, London, W.12

ROWORTH A. J. SPURRELL
B.Sc., M.B., M.R.C.P.

Department of Cardiology, Guy’s Hospital, London, S.E.1

Summary
Verapamyl is a novel antiarrhythmic agent which appears to act as a calcium-ion antagonist, blocking calcium transport across the myocardial cell membrane. It was given intravenously, in a dose of 10 mg, to thirty-two patients suffering from paroxysmal supraventricular tachycardia, and sinus rhythm was achieved promptly in all. Identical results were obtained in a further ten patients with supraventricular tachycardias associated with the Wolff-Parkinson-White or other pre-excitation syndromes. In a separate group of eighteen patients in whom A-V junctional tachycardias were induced during intracardiac electrography, conversion to sinus rhythm was achieved in fifteen patients, with prolongation of the cycle length in the others. Circus-movement tachycardias were induced in eight patients with the Wolff-Parkinson-White syndrome, and conversion to sinus rhythm was achieved in seven. The results were less consistent in patients with other supraventricular arrhythmias including ectopic atrial tachycardia and atrial flutter, and, in the single patient with supraventricular and ventricular tachycardia, only the former was controlled. In the single patient with atrial fibrillation complicating the Wolff-Parkinson-White syndrome who received verapamyl, sinus rhythm was restored. Side effects were few and mild, with rare exceptions of profound hypotension, bradycardia and asystole; their management is discussed, and reasons are advanced why their occurrence is likely to be related either to the concomitant administration of beta-adrenergic blockers or to the presence of sinoatrial disease. It appears that verapamyl is particularly suitable for the treatment of supraventricular tachycardias due to a circus movement as calcium antagonism is likely to be most effective in the N region of the atrioventricular node.

Verapamyl was originally considered to be a coronary vasodilator (Haas and Härtfelder, 1962), and on this basis was introduced for the treatment of cardiac ischaemia (Tschirdevahn and Klepzig, 1963; Hoffmann, 1964). Under experimental conditions, potent antiarrhythmic activity was noted (Melville, Shister and Huq, 1964; Schmid and Hanna, 1967; Kaumann and Aramendi, 1968) and it is now recognized that its antiarrhythmic activity and any action improving cardiac ischaemia is determined by its ability to prevent calcium inflow across the cell membrane (Nayler et al., 1968; Fleckenstein, Döring and Kammermeier, 1968; Nayler and Szeto, 1972; Singh and Vaughan Williams, 1972). In clinical use its antiarrhythmic properties have been demonstrated by Bender et al. (1966) and, in anaesthetized subjects, by Brichard and Zimmerman (1970). Given intravenously, it has been shown to have a potent effect in slowing and regularizing the ventricular response in atrial fibrillation (Schaamroth, 1971; Schaamroth, Krikler and Garrett, 1972).

In the study reported by Schaamroth et al. (1972) twenty patients with paroxysmal supraventricular tachycardia all responded promptly to intravenous verapamyl. We have now extended the number of cases treated, and have included a further group in whom paroxysmal supraventricular tachycardias were induced during intracardiac electrographic studies. The response in some other arrhythmias is also briefly considered.

Methods
Verapamyl was administered intravenously as previously described (Schaamroth et al., 1972). A dose of 10 mg was given over a period of 15–30 sec. In all cases the patients were in the recumbent position, a 12-lead electrocardiogram was first recorded, and the arrhythmia was identified. A continuous electrocardiographic recording was started before the injection and continued until sinus rhythm had been restored, or for at least 5 min. The blood pressure was recorded before, immediately after and on several occasions subsequent to the administration of the verapamyl.

In the patients studied in the laboratory, intracardiac electrographic recordings were made and stimulation carried out as previously described (Spurrell, Krikler and Sowton, 1973). Catheters were passed from the femoral veins and positioned in the right atrium, the right ventricle, and across the tricuspid valve in apposition to the bundle of His; in some patients, transseptal puncture was performed and recordings made from the left atrium. In all
Fig. 1. ECG, showing paroxysmal supraventricular tachycardia at 160 beats a minute, with abrupt conversion to sinus rhythm (100 beats a minute) 40 sec after injection of verapamil.

Fig. 2. ECG, showing paroxysmal supraventricular tachycardia with conversion to sinus rhythm 30 sec after verapamil, with ventricular extrasystole at transition.

Fig. 3. ECG (lead II) showing paroxysmal supraventricular tachycardia (160 beats a minute) in upper panel (0 = prior to injection of verapamil). The middle two panels start 24 and 48 sec after verapamil, respectively, and show persistence of tachycardia pattern with progressive slowing of heart rate down to 84 beats a minute. Note the progressive PR lengthening to 0-48 sec. In the bottom panel (60 sec) sinus rhythm has been restored at a rate of 78 beats a minute, with a normal PR interval of 0-16 sec.

patients the procedure was essential to obtain information in the interests of their health; they were fully informed of what was to be done, and consented to the study. Verapamil was administered in the same dose and tracings recorded as appropriate both from intracardiac electrodes and surface leads, and the response to verapamil noted.

Results
Clinical cases
Thirty-two patients suffered from paroxysmal supraventricular tachycardia due to a circus movement affecting the atrioventricular node, and all responded promptly to the verapamil. Typical responses are shown in Figs. 1 and 2, and consisted either of an abrupt change to sinus rhythm, or one punctuated by the occurrence of one or more ventricular extrasystoles; there was often a brief period of sinus bradycardia, lasting for 30–60 sec. There was occasional evidence of antero-grade A-V nodal conduction delay prior to restoration of sinus rhythm, as is demonstrated in Fig. 3, where progressive PR lengthening occurred with persistence of the tachycardia, until abrupt restoration of sinus rhythm with a normal PR interval.

Mild transient hypotension, with a drop in the
Verapamil and tachycardia

systolic pressure to 80–100 mmHg for 2–3 min, was noted in four patients, but recovery was spontaneous. However, in a further three patients, more marked hypotension, of the order of 60–40 mmHg, was noted, and all these patients were then found to have received oral beta-blocking agents (propranolol or practolol) in normal therapeutic doses on the same day.

Four patients with ectopic atrial tachycardia received verapamil. In one patient, there was conversion to sinus rhythm, preceded by A-V nodal Wenckebach periods (see Fig. 7 in the report by Schamroth et al., 1972). In another patient, in whom the aetiology was congestive cardiomyopathy, the tachycardia was converted to atrial fibrillation which spontaneously changed to sinus rhythm 1 day later; in the other patients, in whom the arrhythmia was believed to be due to thyroxine overdose in one and to cardiac ischaemia in the other, there was a transient increase in the degree of atrioventricular block.

This is similar to our further experience with atrial flutter, which has proved less promising than the original findings (Schamroth et al., 1972). We have administered verapamil to twenty patients, achieving sinus rhythm in five and a transient increase in the degree of atrioventricular block in the remaining fifteen, without altering the cycle length of the flutter waves in any.

A 61-year-old man who suffered from a dual paroxysmal tachycardia of both supraventricular and ventricular origin (Fig. 4), possibly due to digitalis intoxication, responded promptly to intravenous verapamil in that the supraventricular tachycardia was completely controlled, but the ventricular tachycardia persisted (Fig. 5), with consequent haemodynamic deterioration and the need for DC shock.

Ten patients who had reciprocating tachycardias associated with pre-excitation syndromes all responded promptly to intravenous verapamil, with
conversion to sinus rhythm within 2 min. One of these patients, a 68-year-old woman, appears also to have sinoatrial disease as judged by marked sinus bradycardia and sinus arrhythmia and junctional or ventricular escape beats while not receiving anti-arrhythmic medications; paroxysmal supraventricular tachycardia occurred despite the prophylactic oral administration of practolol 400 mg daily. She received 10 mg verapamil intravenously, which produced prompt control of the arrhythmia, but with temporary sinus arrest, necessitating temporary ventricular pacing before sinus rhythm was restored.

An additional observation, in a single case of atrial fibrillation complicating the Wolff-Parkinson-White syndrome, is instructive. A 36-year-old woman had suffered one previous attack of palpitations, and was admitted with an irregular tachycardia with wide QRS complexes (Fig. 6). This has the appearance of atrial fibrillation complicating the Wolff-Parkinson-White syndrome, most of the impulses being conducted totally down the anomalous tract. The response to intravenous verapamil was at first

![Fig. 6. ECGs, lead II, showing response of patient with atrial fibrillation complicating Wolff-Parkinson-White syndrome. O control tracing, with maximal pre-excitation pattern and ventricular response of 230 beats a minute. Four minutes after verapamil, the same pattern persists but the ventricular rate has fallen to 140. At 6 min, junctional rhythm with retrograde P'-waves, at 80 beats a minute; at 10 min, restoration of sinus rhythm with Wolff-Parkinson-White appearances (note negative delta wave), at 72 beats a minute.](http://pmj.bmj.com/)

![Fig. 7. Wolff-Parkinson-White syndrome, Type B, with negative delta wave and dominant S in V1.](http://pmj.bmj.com/)
slowing of the ventricular response (4 min), then development of junctional rhythm with narrow QRS complexes (6 min), and, after 10 min, restoration of sinus rhythm with the pre-excitation pattern (see also Fig. 7).

**Intracardiac studies**

Eighteen patients with A-V junctional tachycardias were given verapamil while in circus-movement tachycardia, and in fifteen patients the tachycardia was terminated within 2–3 min. In the remaining three cases, the cycle length was prolonged in both the anterograde and retrograde directions but reciprocation continued. Cessation of tachycardia could take place with interruption of the circuit either in the anterograde pathway (Fig. 8) or in the retrograde pathway (Fig. 9) within the atrioventricular node. Of these fifteen patients—in whom there was no reason to suspect pre-excitation—the presence of a concealed bypass outside the atrioventricular node was suggested in five by constant ventriculoatrial conduction times which were not influenced by verapamil (Spurrell, Krikler and Sowton, 1974a).

Eight patients with Wolff-Parkinson-White syndrome were given verapamil while in circus-movement tachycardia during laboratory studies, and in seven of these patients the tachycardia was terminated within 2 min. In the remaining patient, a suitably-timed extrasystole was injected in order to disrupt the circuit, as described by Wellens (1971).

**Comment**

Whether circus-movement tachycardia is due to a process involving the atrioventricular node alone, or whether the circuit involves an anomalous pathway as well as the A-V node, verapamil appears to be a highly effective antiarrhythmic agent, acting directly on the A-V node. The onset of action is rapid, and the response prompt. Intracardiac studies show that verapamil has a potent effect in prolonging A-V nodal conduction (Puech, 1972a; Husaini et al., 1973; Roy, Spurrell and Sowton, 1974). However, in a certain number of cases, side effects have been noted, including hypotension, bradycardia and on rare occasions, cardiac arrest (Benaim, 1972; Boothby, Garrard and Pickering, 1972; Sacks and Knelly, 1972). In the majority of such cases, the prior administration of beta-adrenergic blockers appears to have been an important factor. As has been shown by Nayler and Szeto (1972), verapamil and beta-adrenergic blockers both have calcium-antagonistic properties on the cell though working in totally different ways. Whereas verapamil blocks transport of calcium across the cell membrane, beta-blockers interfere with intracellular calcium handling. Separately each has a mild negative inotropic effect; when given together, this is additive (Nayler, 1974).
Another possible mode of adverse reaction to verapamil implies depression of S-A nodal activity. Under normal circumstances, the administration of verapamil has very little if any effect on S-A nodal automaticity (Puech, 1972a; Roy et al., 1974), but if there is sinoatrial disease, it is to be anticipated that any slight inherent tendency to depression will be increased. For this reason verapamil should be used with caution in patients with the 'sick sinus syndrome' who present with supraventricular tachycardia (Husaini et al., 1973), as, indeed, should other drugs. The summation of these effects is well shown in the patient with Wolff-Parkinson-White syndrome and sinoatrial disease in whom transient cardiac standstill was produced after correction of her circus-movement tachycardia.

We have encountered seven other patients in whom there were adverse effects after intravenous verapamil. In four, verapamil had been administered to patients who were already receiving beta-blockers. A 64-year-old patient with the Wolff-Parkinson-White syndrome who had received repeated intravenous injections of practolol and propranolol and who had needed DC cardioversions and triple-beat ventricular pacing, suffered from repeated bouts of tachycardia with rates up to 300 a minute, and episodes of ventricular fibrillation, for 4 days: verapamil produced conversion to sinus rhythm but she collapsed with asystole.

While Puech (1972a) has found atropine regularly to reverse the effect of verapamil on the A-V node, others have found the response to be incomplete (Roy et al., 1974). Atropine 1 mg intravenously should, however, be given if a reaction occurs, followed by intravenous calcium (10–20 ml of 10% solution); an intravenous infusion of isoprenaline may be needed and, rarely, temporary ventricular pacing. The chance of an adverse reaction can be minimized if it can be ensured that the patient has not been receiving a beta-blocker for at least 6 hr prior to the administration of verapamil. Suspicion of sinoatrial disease merits especial caution in the use of verapamil. However, perspective must be maintained, as adverse reactions occur to other antiarrhythmic agents, e.g. beta-adrenergic blockers (Szekely, 1972), and G. C. Sutton (personal communication) has observed hypotension and pulmonary oedema in a patient with paroxysmal supraventricular tachycardia treated with intravenous practolol who failed to return to sinus rhythm. Furthermore, ill patients who have suffered from arrhythmias for a protracted period are likely to have catecholamine depletion, and may well react adversely both to beta-adrenergic blockers and to verapamil, or indeed any substance that decreases the amount of calcium entering or available within the myocardial cell.

The response in atrial fibrillation complicating the Wolff-Parkinson-White syndrome (Fig. 8) was positive but difficult to understand unless it can be inferred that the initial decrease in ventricular rate was due to a blocking action at the atrio-bypass junction and a subsequent antifibrillatory effect on the atrium, restoring sinus rhythm via a phase of junctional rhythm. Verapamil does not lengthen the refractory period of the bypass, tending not to influence it or to produce slight shortening (Spurrell et al., 1974b).

In the vast majority of published reports, results of treatment have been excellent (Abaza et al., 1972; Gotsman et al., 1972; Filias and Zanoni, 1972; Puech, 1972b). Verapamil has been shown to have an important place in the treatment of paroxysmal A-V nodal tachycardia. Our experience has been confined to its intravenous use and we have not made any systematic assessment of its efficacy when given by mouth for treatment or prophylaxis, though others have reported satisfactory results (Bender, 1970; Abaza et al., 1972; Filias and Zanoni, 1972; Puech, 1972b). Its preferential action on the A-V node may be due to the fact that its potent calcium antagonism is most sensitively felt in the N region of the node, where a slow Na\textsuperscript{+}-Ca\textsuperscript{2+} channel determines conduction (Zipes, 1973). Provided precautions are taken in the selection of patients and in the exclusion of those who have recently received beta-adrenergic blockers, use of verapamil in supraventricular tachycardias provides an important and useful form of therapy. Whether the mechanism involves the A-V node alone or the A-V node plus an extranodal bypass, verapamil has been shown to be a safe and effective primary agent for the treatment of circus-movement supraventricular tachycardias.

References


Verapamil and tachycardia


